Yes, I agree that Anteris wants ViV procedures to be included in the EFS or pivotal trial but it's up to the FDA to decide if that will happen or if we will need a separate ViV trial.
Wayne wants to find a shortcut with ViV. Obviously I am extremely skeptical that will happen but with ViV being around 5% of TAVR procedures and probably around 90k US TAVR implantations expected in 2025, the 8,000 devices that can be sold for a profit yearly with an HDE would cover the entire US ViV market. Failing surgically implanted Abbott valves may increase that 5% number but 8,000 valves would still be a very large portion of total US ViV procedures.
AVR Price at posting:
$20.90 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)